Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'TARDIVE' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 1154 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Tan, EK; Ondo, WG
      Motor restlessness

      INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
    2. Haut, F; Clos, S
      Acute akathisia and sodium valproate

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    3. Procyshyn, RM; Flynn, S
      Discharge prescribing practices: Comparing a research ward to general treatment wards

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    4. Rybakowski, JK; Borkowska, A; Czerski, PM; Hauser, J
      Dopamine D3 receptor (DRD3) gene polymorphism is associated with the intensity of eye movement disturbances in schizophrenic patients and healthy subjects

      MOLECULAR PSYCHIATRY
    5. Govoni, S; Racchi, M; Masoero, E; Zamboni, M; Ferini-Strambi, L
      Extrapyramidal symptoms and antidepressant drugs: neuropharmacological aspects of a frequent interaction in the elderly

      MOLECULAR PSYCHIATRY
    6. Segman, RH; Heresco-Levy, U; Finkel, B; Goltser, T; Shalem, R; Schlafman, M; Dorevitch, A; Yakir, A; Greenberg, D; Lerner, A; Lerer, B
      Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia

      MOLECULAR PSYCHIATRY
    7. Basile, VS; Ozdemir, V; Masellis, M; Meltzer, HY; Lieberman, JA; Potkin, SG; Macciardi, FM; Petronis, A; Kennedy, JL
      Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia

      MOLECULAR PSYCHIATRY
    8. Lovlie, R; Thara, R; Padmavathi, R; Steen, VM; McCreadie, RG
      Ser9Gly dopamine D3 receptor polymorphism and spontaneous dyskinesia in never-medicated schizophrenic patients

      MOLECULAR PSYCHIATRY
    9. Herken, H; Uz, E; Ozyurt, H; Sogut, S; Virit, O; Akyol, O
      Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation ape increased in different forms of schizophrenia

      MOLECULAR PSYCHIATRY
    10. Oosthuizen, P; Emsley, RA
      First-episode psychosis: lessons from 15 years of research

      PRIMARY CARE PSYCHIATRY
    11. Wooten, GF
      Anatomy and function of dopamine receptors: understanding the pathophysiology of fluctuations in Parkinson's disease

      PARKINSONISM & RELATED DISORDERS
    12. Krack, P; Vercueil, L
      Review of the functional surgical treatment of dystonia

      EUROPEAN JOURNAL OF NEUROLOGY
    13. Warren, BH; Crews, CK; Schulte, MM
      Managing patients with diabetes mellitus and mental health problems - Administrative and clinical challenges

      DISEASE MANAGEMENT & HEALTH OUTCOMES
    14. Desai, HD; Seabolt, J; Jann, MW
      Smoking in patients receiving psychotropic medications - A pharmacokineticperspective

      CNS DRUGS
    15. Yao, JK; Reddy, RD; van Kammen, DP
      Oxidative damage and schizophrenia - An overview of the evidence and its therapeutic implications

      CNS DRUGS
    16. Arranz, MJ; Mancama, D; Kerwin, RW
      Neurotransmitter receptor variants and their influence on antipsychotic treatment (Review)

      INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
    17. Kennedy, A; Jain, S; Vinogradov, S
      Atypical antipsychotics for schizophrenia: Their collective role and comparative profiles

      FORMULARY
    18. Schneider, LS; Tariot, PN; Lyketsos, CG; Dagerman, KS; Davis, KL; Davis, S; Hsiao, JK; Jeste, DV; Katz, IR; Olin, JT; Pollock, BG; Rabins, PV; Rosenheck, RA; Small, GW; Lebowitz, B; Lieberman, JA
      National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) - Alzheimer disease trial methodology

      AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
    19. Madhusoodanan, S
      Introduction - Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric patients

      AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
    20. Farver, DK; Khan, MH
      Zolpidem for antipsychatic-induced parkinsonism

      ANNALS OF PHARMACOTHERAPY
    21. Bryden, KE; Carrey, NJ; Kutcher, SP
      Update and recommendations for the use of antipsychotics in early-onset psychoses

      JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
    22. Naidu, PS; Kulkarni, SK
      Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide

      BEHAVIOURAL PHARMACOLOGY
    23. Collier, DA; Osborne, S; Munro, J; Kerwin, RW
      Pharmacogenetic methods in schizophrenia

      INTERNATIONAL REVIEW OF PSYCHIATRY
    24. Bullock, R
      Drug treatment in dementia

      CURRENT OPINION IN PSYCHIATRY
    25. Malhotra, AK
      The genetics of schizophrenia

      CURRENT OPINION IN PSYCHIATRY
    26. Kane, JM
      Extrapyramidal side effects are unacceptable

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    27. Chengappa, KNR; Levine, J; Rathore, D; Parepally, H; Atzert, R
      Long-term effects of topiramate on bipolar mood instability, weight changeand glycemic control: a case-series

      EUROPEAN PSYCHIATRY
    28. Bergiannaki, JD; Hatzimanolis, J; Liappas, J; Sakkas, PN; Stefanis, CN
      Relapse prevention in schizophrenia: attitudes of neurologists-psychiatrists

      EUROPEAN PSYCHIATRY
    29. Schulze, TG; Muller, DJ; Krauss, H; Marwinski, K; Maroldt, AO; Fernandez, ANY; Fimmers, R; Held, T; Maier, W; Nothen, MM; Rietschel, M
      Affective symptomatology in schizophrenia: a risk factor for tardive dyskinesia?

      EUROPEAN PSYCHIATRY
    30. Salzman, C
      Treatment of the agitation of late-life psychosis and Alzheimer's disease

      EUROPEAN PSYCHIATRY
    31. McGlashan, TH
      Psychosis treatment prior to psychosis onset: ethical issues

      SCHIZOPHRENIA RESEARCH
    32. Peet, M; Brind, J; Ramchand, CN; Shah, S; Vankar, GK
      Two double-blind placebo-controlled pilot studies of eicosapentaenoic acidin the treatment of schizophrenia

      SCHIZOPHRENIA RESEARCH
    33. Quinn, J; Meagher, D; Murphy, P; Kinsella, A; Mullaney, J; Waddington, JL
      Vulnerability to involuntary movements over a lifetime trajectory of schizophrenia approaches 100%, in association with executive (frontal) dysfunction

      SCHIZOPHRENIA RESEARCH
    34. Dahmen, N; Muller, MJ; Germeyer, S; Rujescu, D; Anghelescu, I; Hiemke, C; Wetzel, H
      Genetic polymorphisms of the dopamine D-2 and D-3 receptor and neurolepticdrug effects in schizophrenic patients

      SCHIZOPHRENIA RESEARCH
    35. Salyers, MP; Mueser, KT
      Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia

      SCHIZOPHRENIA RESEARCH
    36. Srinivasan, TN; Thara, R; Padmavathi, R; McCreadie, RG
      Relationship of extrapyramidal symptoms to age at onset and drug treatmentin middle-aged and elderly schizophrenic patients

      SCHIZOPHRENIA RESEARCH
    37. Bodfish, JW; Parker, DE; Lewis, MH; Sprague, RL; Newell, KM
      Stereotypy and motor control: Differences in the postural stability dynamics of persons with stereotyped and dyskinetic movement disorders

      AMERICAN JOURNAL ON MENTAL RETARDATION
    38. Lindamer, LA; Lohr, JB; Caligiuri, MP; Jeste, DV
      Relationship of gender and age at onset of schizophrenia to severity of dyskinesia

      JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
    39. Barbaccia, ML; Affricano, D; Purdy, RH; Maciocco, E; Spiga, F; Biggio, G
      Clozapine, but not haloperidol, increases brain concentrations of neuroactive steroids in the rat

      NEUROPSYCHOPHARMACOLOGY
    40. Scheepers, FE; de Wied, CCG; Pol, HEH; van de Flier, W; van der Linden, JA; Kahn, RS
      The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics

      NEUROPSYCHOPHARMACOLOGY
    41. Malone, RP; Cater, J; Sheikh, RM; Choudhury, MS; Delaney, MA
      Olanzapine versus haloperidol in children with autistic disorder: An open pilot study

      JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
    42. Sakai, K; Gao, XM; Hashimoto, T; Tamminga, CA
      Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways

      SYNAPSE
    43. Roberts, RC
      Effect of chronic olanzapine treatment on striatal synaptic organization

      SYNAPSE
    44. Grimm, JW; Chapman, MA; Zahm, DS; See, RE
      Decreased choline acetyltransferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats

      SYNAPSE
    45. Hansen, L
      A critical review of akathisia, and its possible association with suicidalbehaviour

      HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
    46. Schultz, SK; Ellingrod, V; Fleming, FW; Andreasen, NC
      The association between risk factors for tardive dyskinesia and phenylalanine-induced abnormal movements in schizophrenia

      HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
    47. Tariot, PN; Ryan, JM; Porsteinsson, AP; Loy, R; Schneider, LS
      Pharmacologic therapy for behavioral symptoms of Alzheimer's disease

      CLINICS IN GERIATRIC MEDICINE
    48. Mahant, PR; Stacy, MA
      Movement disorders and normal aging

      NEUROLOGIC CLINICS
    49. Higgins, DS
      Chorea and its disorders

      NEUROLOGIC CLINICS
    50. Goetz, CG; Horn, SS
      Treatment of tremor and dystonia

      NEUROLOGIC CLINICS
    51. Friedlander, R; Lazar, S; Klancnik, J
      Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities

      CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
    52. Ahmed, AG; Heigh, LM; Ramachandran, KV
      Polydipsia, psychosis, and familial psychopathology

      CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
    53. Procyshyn, RM; Kennedy, NB; Tse, G; Thompson, B
      Antipsychotic polypharmacy: A survey of discharge prescriptions from a tertiary care psychiatric institution

      CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
    54. Rascol, O; Fabre, N
      Dyskinesia: L-dopa-induced and tardive dyskinesia

      CLINICAL NEUROPHARMACOLOGY
    55. Miyata, S; Hamamura, T; Yoshinaga, J; Nakamura, Y; Imamura, T; Hikiji, A; Kuroda, S
      Amelioration of frozen gait by tandospirone, a serotonin 1A agonist, in a patient with pure akinesia developing resistance to L-threo-3,4-dihydroxyphenylserine

      CLINICAL NEUROPHARMACOLOGY
    56. Sutcher, H
      Prosthetic dentistry in the treatment of movement disorders: dyskinesias and other neurological abnormalities

      MEDICAL HYPOTHESES
    57. Bayas, A; Kornhuber, J; Naumann, M
      Atypical neuroleptics and new antidepressants in the treatment of neurological disorders

      AKTUELLE NEUROLOGIE
    58. Iwahashi, K; Anemo, K; Nakamura, K; Fukunishi, I; Igarashi, K
      Analysis of the metabolism of haloperidol and its neurotoxic pyridinium metabolite in patients with, drug-induced parkinsonism

      NEUROPSYCHOBIOLOGY
    59. Liao, DL; Yeh, YC; Chen, HM; Chen, H; Hong, CJ; Tsai, SJ
      Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

      NEUROPSYCHOBIOLOGY
    60. Berg, D; Becker, G; Naumann, M; Reiners, K
      Morphine in tardive and idiopathic dystonia

      JOURNAL OF NEURAL TRANSMISSION
    61. Garcia-Barcelo, MM; Lam, LCW; Ungvari, GS; Lam, VKL; Tang, WK
      Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

      JOURNAL OF NEURAL TRANSMISSION
    62. Fukasawa, T; Takahashi, M; Otani, K
      A successful clonazepam treatment without tolerance in a patient with spontaneous oral dyskinesia

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    63. Mahadik, SP; Evans, D; Lal, H
      Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    64. Sethi, KD
      Movement disorders induced by dopamine blocking agents

      SEMINARS IN NEUROLOGY
    65. Wassef, AA; Hafiz, NG; Hampton, D; Molloy, M
      Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: Clinical and economic implications

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    66. Zhang, XY; Zhou, DF; Su, JM; Zhang, PY
      The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    67. Mehta, A; Bot, G; Reisine, T; Chesselet, MF
      Endomorphin-1: Induction of motor behavior and lack of receptor desensitization

      JOURNAL OF NEUROSCIENCE
    68. Uzun, O; Cansever, A; Ozsahin, A
      A case of relapsed tardive dyskinesia due to clozapine dose reduction

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    69. Lam, LCW; Garcia-Barcelo, MM; Ungvari, GS; Tang, WK; Lam, VKL; Kwong, SL; Lau, BST; Kwong, PPK; Waye, MMY; Chiu, HFK
      Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients

      PHARMACOPSYCHIATRY
    70. Tohen, M; Zhang, F; Taylor, CC; Burns, P; Zarate, C; Sanger, T; Tollefson, G
      A meta-analysis of the use of typical antipsychotic agents in bipolar disorder

      JOURNAL OF AFFECTIVE DISORDERS
    71. Ozdemir, V; Basile, VS; Masellis, M; Kennedy, JL
      Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes

      JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS
    72. Sajatovic, M; Brescan, DW; Perez, DE; DiGiovanni, SK; Hattab, H; Ray, JB; Bingham, CR
      Quetiapine alone and added to a mood stabilizer for serious mood disorders

      JOURNAL OF CLINICAL PSYCHIATRY
    73. Vieta, E; Herraiz, M; Fernandez, A; Gasto, C; Benabarre, A; Colom, F; Martinez-Aran, A; Reinares, M
      Efficacy and safety of risperidone in the treatment of schizoaffective disorder: Initial results from a large, multicenter surveillance study

      JOURNAL OF CLINICAL PSYCHIATRY
    74. Sanger, TM; Grundy, SL; Gibson, PJ; Namjoshi, MA; Greaney, MG; Tohen, MF
      Long-term olanzapine therapy in the treatment of bipolar I disorder: An open-label continuation phase study

      JOURNAL OF CLINICAL PSYCHIATRY
    75. Budman, CL; Gayer, A; Lesser, M; Shi, QH; Bruun, RD
      An open-label study of the treatment efficacy of olanzapine for Tourette'sdisorder

      JOURNAL OF CLINICAL PSYCHIATRY
    76. Wirshing, WC
      Movement disorders associated with neuroleptic treatment

      JOURNAL OF CLINICAL PSYCHIATRY
    77. De Deyn, PP; Wirshing, WC
      Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia

      JOURNAL OF CLINICAL PSYCHIATRY
    78. Mintzer, JE
      Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease

      JOURNAL OF CLINICAL PSYCHIATRY
    79. Tune, LE
      Risperidone for the treatment of behavioral and psychological symptoms of dementia

      JOURNAL OF CLINICAL PSYCHIATRY
    80. Kinon, BJ; Roychowdhury, SM; Milton, DR; Hill, AL
      Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia

      JOURNAL OF CLINICAL PSYCHIATRY
    81. Hori, H; Ohmori, O; Shinkai, T; Kojima, H; Nakamura, J
      Association between three functional polymorphisms of dopamine D2 receptorgene and tardive dyskinesia in schizophrenia

      AMERICAN JOURNAL OF MEDICAL GENETICS
    82. Ozdemir, V; Shear, NH; Kalow, W
      What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?

      DRUG SAFETY
    83. Phillips, KA; Veenstra, DL; Oren, E; Lee, JK; Sadee, W
      Potential role of pharmacogenomics in reducing adverse drug reactions - A systematic review

      JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    84. Mehta, A; Eberle-Wang, K; Chesselet, MF
      Increased m-CPP-induced oral dyskinesia after lesion of serotonergic neurons

      PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
    85. Kapur, S; Remington, G
      Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia

      ANNUAL REVIEW OF MEDICINE
    86. Agarwal, V; Sitholey, P; Kumar, S; Prasad, M
      Double-blind, placebo-controlled trial of clonidine in hyperactive children with mental retardation

      MENTAL RETARDATION
    87. Nelson, DE
      Akathisia - A brief review

      SCOTTISH MEDICAL JOURNAL
    88. Jahnel, M
      H.A. Huntington's disease relevant differential diagnosis in geropsychiatric patients?

      NERVENARZT
    89. Goff, DC; Heckers, S; Freudenreich, O
      Schizophrenia

      MEDICAL CLINICS OF NORTH AMERICA
    90. Sutor, B; Rummans, TA; Smith, GE
      Assessment and management of behavioral disturbances in nursing home patients with dementia

      MAYO CLINIC PROCEEDINGS
    91. Trottenberg, T; Paul, G; Meissner, W; Maier-Hauff, K; Taschner, C; Kupsch, A
      Pallidal and thalamic neurostimulation in severe tardive dystonia

      JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
    92. Henry, B; Fox, SH; Crossman, AR; Brotchie, JM
      mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

      EXPERIMENTAL NEUROLOGY
    93. Rodriguez, JJ; Garcia, DR; Nakabeppu, Y; Pickel, VM
      Enhancement of laminar FosB expression in frontal cortex of rats receivinglong chronic clozapine administration

      EXPERIMENTAL NEUROLOGY
    94. Naidu, PS; Kulkarni, SK
      Possible involvement of prostaglandins in haloperidol-induced orofacial dyskinesia in rats

      EUROPEAN JOURNAL OF PHARMACOLOGY
    95. Bymaster, FP; Falcone, JF; Bauzon, D; Kennedy, JS; Schenck, K; DeLapp, NW; Cohen, ML
      Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine

      EUROPEAN JOURNAL OF PHARMACOLOGY
    96. Naidu, PS; Kulkarni, SK
      Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements

      EUROPEAN JOURNAL OF PHARMACOLOGY
    97. Naidu, PS; Kulkarni, SK
      Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists

      EUROPEAN JOURNAL OF PHARMACOLOGY
    98. Cookson, J
      Use of antipsychotic drugs and lithium in mania

      BRITISH JOURNAL OF PSYCHIATRY
    99. Raghavendra, V; Naidu, PS; Kulkarni, SK
      Reversal of reserpine-induced vacuous chewing movements in rats by melatonin: involvement of peripheral benzodiazepine receptors

      BRAIN RESEARCH
    100. Tan, EC; Chong, SA; Mahendran, R; Dong, F; Tan, CH
      Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor

      BIOLOGICAL PSYCHIATRY


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/10/20 alle ore 08:37:30